Advanced Material Catheter (AMCath), a minimally invasive endocardial catheter for the delivery of fast-gelling covalently cross-linked hyaluronic acid hydrogels
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- Hydrogel, catheter, hyaluronic acid, minimally invasive delivery, myocardial infarction,
- MeSH
- Biocompatible Materials administration & dosage MeSH
- Cell Line MeSH
- Equipment Design MeSH
- Hydrogels administration & dosage MeSH
- Cells, Immobilized cytology transplantation MeSH
- Myocardial Infarction therapy MeSH
- Injections MeSH
- Stem Cells cytology MeSH
- Hyaluronic Acid administration & dosage MeSH
- Drug Delivery Systems instrumentation MeSH
- Humans MeSH
- Swine MeSH
- Cross-Linking Reagents administration & dosage MeSH
- Cardiac Catheters * MeSH
- Stem Cell Transplantation MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Biocompatible Materials MeSH
- Hydrogels MeSH
- Hyaluronic Acid MeSH
- Cross-Linking Reagents MeSH
Injectable hydrogels that aim to mechanically stabilise the weakened left ventricle wall to restore cardiac function or to deliver stem cells in cardiac regenerative therapy have shown promising data. However, the clinical translation of hydrogel-based therapies has been limited due to difficulties injecting them through catheters. We have engineered a novel catheter, Advanced Materials Catheter (AMCath), that overcomes translational hurdles associated with delivering fast-gelling covalently cross-linked hyaluronic acid hydrogels to the myocardium. We developed an experimental technique to measure the force required to inject such hydrogels and determined the mechanical/viscoelastic properties of the resulting hydrogels. The preliminary in vivo feasibility of delivering fast-gelling hydrogels through AMCath was demonstrated by accessing the porcine left ventricle and showing that the hydrogel was retained in the myocardium post-injection (three 200 μL injections delivered, 192, 204 and 183 μL measured). However, the mechanical properties of the hydrogels were reduced by passage through AMCath (≤20.62% reduction). We have also shown AMCath can be used to deliver cardiopoietic adipose-derived stem cell-loaded hydrogels without compromising the viability (80% viability) of the cells in vitro. Therefore, we show that hydrogel/catheter compatibility issues can be overcome as we have demonstrated the minimally invasive delivery of a fast-gelling covalently cross-linked hydrogel to the beating myocardium.
Boston Scientific Ballybrit Business Park Ballybrit Galway Ireland
Cellular and Molecular Imaging Core Royal College of Surgeons in Ireland Dublin Ireland
Celyad SA Mont Saint Guibert Belgium
Explora Biotech Srl G Peroni Rome Italy
R and D department Contipro Dolni Dobrouc Czech Republic
School of Pharmacy Royal College of Surgeons in Ireland Dublin Ireland
References provided by Crossref.org